Education
About Us
Working with TipRanks
Follow Us
Genedx Holdings Corp. (WGS)
:WGS
WGS Stock Chart & Stats
$151.51
-$4.29(-4.42%)
At close: 4:00 PM EST
$151.51
-$4.29(-4.42%)
Day’s Range― - ―
52-Week Range$55.17 - $170.87
Previous CloseN/A
Volume338.68K
Average Volume (3M)461.12K
Market Cap
$4.49B
Enterprise Value$3.06B
Total Cash (Recent Filing)$155.08M
Total Debt (Recent Filing)$113.16M
Price to Earnings (P/E)2512.6
Beta1.57
Next Earnings
Mar 17, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.49
Shares Outstanding28,904,590
10 Day Avg. Volume373,965
30 Day Avg. Volume461,116
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)8.43
Price to Sales (P/S)6.77
P/FCF Ratio-60.81
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue7.61
Enterprise Value/Gross Profit10.93
Enterprise Value/Ebitda96.23
Forecast
1Y Price Target
$161.07Price Target Upside6.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)1.38
Revenue Forecast (FY)$426.93M
Bulls Say, Bears Say
Bulls Say
EarningsBetter than projected Q3 earnings drive increased confidence in FY '26 and beyond, maintaining a BUY rating and increasing the price target to $153.
Market PositionGeneDx was selected to participate in the Sunshine Genetics Network, the first state-backed newborn screening program, which could enhance its market position.
Revenue GrowthGeneDx reported third-quarter results that were well ahead of estimates and consensus, with significant revenue growth of 52% year-over-year.
Bears Say
EBITDA EstimatesWhile revenue estimates for Q4 and 2026 are increasing, adjusted EBITDA estimates for both periods are being lowered to reflect incremental investments related to the general pediatrics opportunity.
Investor ApprehensionThe outlook for higher operating expenses as WGS plans to penetrate the pediatrician market has caused some investor apprehension.
Operating ExpensesOperating expenses increased over 20% relative to 2Q25, with further increases expected.
GeneDx Holdings News
WGS FAQ
What was Genedx Holdings Corp.’s price range in the past 12 months?
Genedx Holdings Corp. lowest stock price was $55.17 and its highest was $170.87 in the past 12 months.
What is Genedx Holdings Corp.’s market cap?
Genedx Holdings Corp.’s market cap is $4.49B.
When is Genedx Holdings Corp.’s upcoming earnings report date?
Genedx Holdings Corp.’s upcoming earnings report date is Mar 17, 2026 which is in 94 days.
How were Genedx Holdings Corp.’s earnings last quarter?
Genedx Holdings Corp. released its earnings results on Oct 28, 2025. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.423 by $0.067.
Is Genedx Holdings Corp. overvalued?
According to Wall Street analysts Genedx Holdings Corp.’s price is currently Undervalued.
Does Genedx Holdings Corp. pay dividends?
Genedx Holdings Corp. does not currently pay dividends.
What is Genedx Holdings Corp.’s EPS estimate?
Genedx Holdings Corp.’s EPS estimate is 0.09.
How many shares outstanding does Genedx Holdings Corp. have?
Genedx Holdings Corp. has 28,904,590 shares outstanding.
What happened to Genedx Holdings Corp.’s price movement after its last earnings report?
Genedx Holdings Corp. reported an EPS of $0.49 in its last earnings report, beating expectations of $0.423. Following the earnings report the stock price went up 5.212%.
Which hedge fund is a major shareholder of Genedx Holdings Corp.?
Currently, no hedge funds are holding shares in WGS
GeneDx Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$161.07 (6.31% Upside)
$161.07 (6.31% Upside)
Blogger Sentiment
Bullish
WGS Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 183.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
111.10%
12-Months-Change
Fundamentals
Return on Equity
0.84%
Trailing 12-Months
Asset Growth
20.81%
Trailing 12-Months
Company Description
Genedx Holdings Corp.
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
WGS Company Deck
WGS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance with significant revenue growth and improved margins. The FDA breakthrough designation adds further validation to GeneDx's technology. However, potential ASP declines and market underpenetration in NICUs were noted challenges. Overall, the highlights outweigh the lowlights, indicating a positive outlook.View all WGS earnings summariesWGS Revenue Breakdown
96.59% Diagnostic test revenue
3.41% Other
WGS Stock 12 Month Forecast
Average Price Target
$161.07
▲(6.31% Upside)
Technical Analysis
Evolent Health
―
10x Genomics
―
Certara
―
SOPHiA GENETICS
―
BrightSpring Health Services, Inc.
―
Ownership Overview
48.73% Insiders
18.52% Mutual Funds
22.02% Other Institutional Investors
1.17% Public Companies and Individual Investors